These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 12413638)
21. Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months. Luckhoff H; Phahladira L; Scheffler F; Asmal L; du Plessis S; Chiliza B; Kilian S; Emsley R Schizophr Res; 2019 Apr; 206():171-176. PubMed ID: 30503765 [TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. Jones H; Curtis VA; Wright P; Lucey JV Am J Psychiatry; 1998 Jun; 155(6):838-40. PubMed ID: 9619161 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic Response Is Associated With Antipsychotic-Induced Weight Gain in Drug-Naive First-Episode Patients With Schizophrenia: An 8-Week Prospective Study. Chen YQ; Li XR; Zhang L; Zhu WB; Wu YQ; Guan XN; Xiu MH; Zhang XY J Clin Psychiatry; 2021 May; 82(3):. PubMed ID: 34004092 [TBL] [Abstract][Full Text] [Related]
24. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303 [TBL] [Abstract][Full Text] [Related]
25. Antipsychotic-induced weight gain and therapeutic response: a differential association. Czobor P; Volavka J; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Cooper TB; Chakos M; Lieberman JA J Clin Psychopharmacol; 2002 Jun; 22(3):244-51. PubMed ID: 12006893 [TBL] [Abstract][Full Text] [Related]
26. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421 [TBL] [Abstract][Full Text] [Related]
27. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354 [TBL] [Abstract][Full Text] [Related]
28. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Suzuki T; Remington G; Arenovich T; Uchida H; Agid O; Graff-Guerrero A; Mamo DC Br J Psychiatry; 2011 Oct; 199(4):275-80. PubMed ID: 22187729 [TBL] [Abstract][Full Text] [Related]
29. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Hagger C; Buckley P; Kenny JT; Friedman L; Ubogy D; Meltzer HY Biol Psychiatry; 1993 Nov; 34(10):702-12. PubMed ID: 8292674 [TBL] [Abstract][Full Text] [Related]
30. The effects of clozapine on symptom clusters in treatment-refractory patients. Abraham G; Nair C; Tracy JI; Simpson GM; Josiassen RC J Clin Psychopharmacol; 1997 Feb; 17(1):49-53. PubMed ID: 9004057 [TBL] [Abstract][Full Text] [Related]
31. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. Procyshyn RM; Wasan KM; Thornton AE; Barr AM; Chen EY; Pomarol-Clotet E; Stip E; Williams R; Macewan GW; Birmingham CL; Honer WG; J Psychiatry Neurosci; 2007 Sep; 32(5):331-8. PubMed ID: 17823649 [TBL] [Abstract][Full Text] [Related]
32. Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment. Garriga M; Mallorquí A; Bernad S; Ruiz-Cortes V; Oliveira C; Amoretti S; Mezquida G; Bioque M; Molina O; Gómez-Ramiro M; Vieta E; Bernardo M; Parellada E; García-Rizo C J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):75-80. PubMed ID: 34928563 [TBL] [Abstract][Full Text] [Related]
34. [Clozapine and refractory schizophrenia. Long-term prospective study of 20 patients]. Jalenques I; Coudert AJ Encephale; 1994; 20(6):767-75. PubMed ID: 7875111 [TBL] [Abstract][Full Text] [Related]
35. Clozapine and weight gain. Umbricht DS; Pollack S; Kane JM J Clin Psychiatry; 1994 Sep; 55 Suppl B():157-60. PubMed ID: 7961563 [TBL] [Abstract][Full Text] [Related]
36. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Meltzer HY; Arvanitis L; Bauer D; Rein W; Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685 [TBL] [Abstract][Full Text] [Related]
37. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885 [TBL] [Abstract][Full Text] [Related]
38. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Baymiller SP; Ball P; McMahon RP; Buchanan RW Schizophr Res; 2003 Jan; 59(1):49-57. PubMed ID: 12413642 [TBL] [Abstract][Full Text] [Related]
39. Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial. Takeuchi H; Lee J; Fervaha G; Foussias G; Agid O; Remington G J Clin Psychiatry; 2017 Feb; 78(2):223-228. PubMed ID: 28234436 [TBL] [Abstract][Full Text] [Related]
40. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]